Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

AbstractPurpose of ReviewGram-negative resistance is a growing concern globally. Enterobacterales, formerlyEnterobacteriaceae, have developed resistance mechanisms to carbapenems that leave very few antimicrobial options in the clinician ’s armamentarium.Recent FindingsNew antimicrobials like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and plazomicin have the potential to overcome resistance mechanisms in Enterobacterales including different classes of carbapenemases.SummaryNovel β-lactam/β-lactamase inhibitors, plazomicin, and cefiderocol give the clinician options that were once not available. Utilizing these options is of the utmost importance when treating carbapenem-resistant Enterobacterales.
Source: Current Infectious Disease Reports - Category: Infectious Diseases Source Type: research